HNSCC (N = 81) | Controls/Tonsils (N = 74) | P | ||
---|---|---|---|---|
Age (mean ± sd) | 62.78 ± 11.24 | 27.19 ± 19.26 | <0.001 | |
Sex | Male | 53 | 40 | 0.200 |
Female | 28 | 34 | ||
Cyclin A1 overexpression (abs./%) | Total | 24/29.6 | 4/5.4 | <0.001 |
Category 0 (negative) | 0/0.0 | 2/2.7 | ||
Category 1 (few positive cells) | 4/4.9 | 9/12.2 | ||
Category 2 (< 10%) | 25/30.9 | 34/45.9 | ||
Category 3 (10-20%) | 28/34.6 | 25/33.8 | ||
Category 4 (20-30%) | 14/17.3 | 4/5.4 | ||
Category 5 (30-40%) | 5/6.2 | 0/0.0 | ||
Category 6 (40-50%) | 3/3.7 | 0/0.0 | ||
Category 7 (50-60%) | 1/1.2 | 0/0.0 | ||
Category 8 (60-70%) | 1/1.2 | 0/0.0 | ||
Category 9 (70-80%) | 0/0.0 | 0/0.0 | ||
Category 10 (80-90%) | 0/0.0 | 0/0.0 | ||
Category 11 (90-100%) | 0/0.0 | 0/0.0 | ||
HPV16 positive (abs./%) | Total | 37/45.7 | 0/0.0 | |
P16 positive | 29 out of 37/78.4 | |||
Cyclin A1 positive | 18 out of 37/48.6 | |||
HPV16 negative (abs./%) | Total | 44/54.3 | 74/100.0 | |
P16 positive | 4 out of 44/9.1 | 0 out of 74/0.0 | ||
Cyclin A1 positive | 6 out of 44/13.6 | 4 out of 74/5.4 | ||
P16 overexpression (abs./%) | Total | 33 out of 79/41.8 | 0/0.0 | |
HPV16 negative | 4 out of 33/12.1 | |||
P53 overexpression (abs./%) | Total | 33 out of 80/41.3 | 0/0.0 | |
HPV16 positive | 4 out of 33/12.1 | |||
P53 mutation (abs./%) | Total | 19 out of 41/46.3 | 0 out of 30/0.0 | |
HPV16 positive | 4 out of 19/21.1 | |||
P53 positive | 9 out of 19/47.4 |